When Evidence Gets Ignored: A Critical Look at Psychedelic Therapy Policy in Australia

Why This Matters

Mental health treatment in Australia is at a crossroads.

Rates of depression, PTSD, and suicide remain high, while many patients don’t respond to existing treatments. At the same time, a growing body of research suggests that psychedelic-assisted therapies—particularly MDMA and psilocybin—may offer real hope.

Yet in 2020, the Royal Australian and New Zealand College of Psychiatrists (RANZCP) released a Clinical Memorandum advising that these therapies should not be used outside research settings.

That recommendation has had real consequences. It has influenced regulators, shaped public perception, and limited access for patients with few remaining options.

So the obvious question is:

👉 Is that position actually supported by the evidence?

This blog breaks down a detailed critique of that memorandum and what it reveals.

The Core Problem: A Mismatch Between Claims and Evidence

After systematically reviewing the memorandum and checking every reference it cites, a clear pattern emerges:

  • Claims that don’t match the underlying studies
  • Selective use of evidence
  • Reliance on outdated or incomplete data
  • Failure to distinguish between recreational drug use and controlled medical therapy

These aren’t minor issues—they fundamentally shape the conclusions.

1. Is MDMA “Not a Psychedelic”?

The memorandum claims MDMA is “not technically a psychedelic.”

That sounds precise—but it doesn’t hold up.

MDMA:

  • Acts on serotonin systems, including 5-HT2A receptors
  • Shares mechanisms with known psychedelics
  • Is widely studied and used within psychedelic-assisted psychotherapy frameworks

The classification used in the memorandum leans more on legal framing than pharmacology.

👉 Why does this matter?
Because how a drug is defined influences how its risks, benefits, and legitimacy are interpreted.

2. “Psychedelics Are Illicit” — Not So Simple

The memorandum presents psychedelics as broadly “illicit.”

But the reality is far more complex:

  • Ketamine is legally prescribed in Australia
  • Ibogaine is prescription-only in Australia and NZ
  • DMT-containing plants appear in approved medicines
  • Harmala alkaloids exist within therapeutic frameworks

Even MDMA and psilocybin can be accessed under Special Access Scheme pathways.

👉 The takeaway:
“Illicit” is an oversimplification that ignores existing medical and regulatory nuance.

3. The Safety Question: What the Evidence Actually Shows

MDMA

In clinical settings:

  • Serious adverse events are rare
  • No evidence of dependence in therapeutic use
  • No increase in illicit drug use post-treatment

Compare that to recreational settings:

  • Unknown purity
  • Polysubstance use
  • No medical screening

👉 These are completely different risk environments—but the memorandum often treats them as interchangeable.

Psilocybin and Psychosis: A Key Misrepresentation

The memorandum links psychedelics to psychosis and HPPD.

But when you actually check the cited studies:

  • The referenced papers do not show psilocybin causing these outcomes in clinical settings
  • A meta-analysis of 40,783 cases found:
    • Only 0.5% linked to hallucinogens
    • All in uncontrolled environments

Even more striking:

  • A study of 135,000 people found no increased risk of mental illness from psychedelic use

👉 The issue isn’t that risks don’t exist—it’s that the evidence was stretched beyond what it supports.

Toxicity: Surprisingly Low

Psilocybin:

  • Estimated lethal dose ≈ 300× therapeutic dose
  • Only two confirmed overdose deaths worldwide since 1960

Meanwhile, in a single year in Australia:

  • Hundreds of deaths linked to antidepressants and anti-anxiety meds

👉 That doesn’t mean psychedelics are risk-free.
But it does mean their risk profile is not being fairly contextualised.

4. The “Not Enough Research” Argument

Yes—more research is always good.

But here’s what already exists:

  • Phase 3 clinical trials
  • FDA “breakthrough therapy” designation
  • 60–80% remission rates in treatment-resistant conditions
  • Dozens of completed studies across multiple countries

At what point does “more research needed” become:

👉 a reason to delay rather than a reason to act?

5. A Double Standard in Medicine

Many widely used treatments have unclear mechanisms, including:

  • Paracetamol
  • Lithium
  • General anaesthetics
  • Modafinil

Some even have known long-term toxicity risks.

Yet they are routinely prescribed.

👉 So why is a higher evidentiary bar applied here?

6. The Real-World Consequence: Patients Left Behind

This isn’t just academic.

When access is restricted:

  • Patients may turn to self-medication
  • Treatment-resistant individuals remain without options
  • Harm may increase—not decrease

Regulators have already acknowledged this risk in other contexts.

👉 Controlled access can be a harm-reduction strategy, not just a clinical one.

7. So What Should Change?

This critique doesn’t argue for reckless adoption.

It argues for:

  • Accurate representation of evidence
  • Clear distinction between clinical and recreational risk
  • Consideration of case-by-case access under strict regulation
  • Ongoing research alongside responsible clinical pathways

Final Thought

The issue isn’t whether psychedelic therapies are perfect.

It’s whether policy is being shaped by the best available evidence—or by an incomplete version of it.

Because when the evidence is misrepresented, the cost isn’t abstract.

👉 It’s paid by patients who are still waiting for something that works.

Back to blog